Patients' understanding of risk.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Focus groups highlight that many patients object to clinicians' focusing on costs.Health affairs (Project Hope) · 2013
   Article
2. Patient adherence to aromatase inhibitor treatment in the adjuvant setting.Current oncology (Toronto, Ont.) · 2011
   Article
3. Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group study.BMC public health · 2010
   Article
4. Insecurity and risk in the consultation.The British journal of general practice : the journal of the Royal College of General Practitioners · 2009
   Article
5. "Please, I want to go home": ethical issues raised when considering choice of place of care in palliative care.Postgraduate medical journal · 2007
   Review
6. Clinical risk management of herb-drug interactions.British journal of clinical pharmacology · 2007
   Review
7. An assessment of risk understanding in Hispanic genetic counseling patients.Journal of genetic counseling · 2005
   Article
8. Challenging times for food allergy tests.Archives of disease in childhood · 2005
   Review
9. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.British journal of cancer · 2005
   Article
10. Screening for breast cancer.JAMA · 2005
    Review
11. Communicating risk: we as doctors are not alone.BMJ (Clinical research ed.) · 2003
    Article

Corrections and comments

• Commented on by
  Communicating risk: we as doctors are not alone.2003

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as